Advent Technologies (ADN) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
10 Jan, 2026Opening remarks and agenda
Meeting convened at 9:00 A.M. on December 31, 2024, with a welcome from the CEO and introduction of the Inspector of Elections.
Only registered stockholders were eligible to vote, and the agenda included director election, auditor ratification, and other business matters.
Board and executive committee updates
Election of one director to serve until the 2027 annual meeting was on the agenda, with Robert Schwartz nominated.
Overview of voting outcomes
Quorum established with 52.61% of outstanding shares represented.
Robert Schwartz elected as Class I director with a majority of votes; 320,810 for, 336,605 withheld, 729,876 broker non-votes.
Ratification of M&K CPAS, PLLC as independent auditor approved by majority; 942,513 for, 440,522 against, 4,256 abstaining.
Proposal regarding other business matters did not receive approval; 256,801 against, 25,359 withheld, 729,876 broker non-votes.
Latest events from Advent Technologies
- Q4 revenue and cash fell as cost cuts and partnerships drove a shift to licensing and MEA focus.ADN
Q4 202323 Jan 2026 - Shareholders will vote on director elections, auditor ratification, stock issuance, and incentive plan changes.ADN
Proxy Filing1 Dec 2025 - Annual meeting to elect a director, ratify auditor, and address other business, all board-recommended.ADN
Proxy Filing1 Dec 2025 - Seeks up to $52M equity funding amid losses and going concern risk, leveraging HT-PEM tech and partnerships.ADN
Registration Filing28 Nov 2025 - Liquidity crisis persists despite improved net income; delisted, high debt, and major legal risks remain.ADN
Q3 202517 Nov 2025 - All agenda items, including director elections and plan amendments, were approved by majority vote.ADN
AGM 202522 Oct 2025 - Severe liquidity challenges, legal settlements, and a major EU grant defined the quarter.ADN
Q2 202512 Aug 2025 - Severe liquidity challenges persist despite cost cuts and a major EU grant, with going concern risks looming.ADN
Q1 202530 Jun 2025 - Revenue up 113% year-over-year, but severe liquidity risk and going concern doubts persist.ADN
Q4 202530 Jun 2025